Xeris Biopharma (NASDAQ:XERS – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Xeris Biopharma to similar companies based on the strength of its analyst recommendations, institutional ownership, profitability, risk, valuation, dividends and earnings.
Earnings & Valuation
This table compares Xeris Biopharma and its peers gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Xeris Biopharma | $291.85 million | $550,000.00 | -337.24 |
| Xeris Biopharma Competitors | $3.56 billion | $3.18 billion | 556.74 |
Xeris Biopharma’s peers have higher revenue and earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Xeris Biopharma and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xeris Biopharma | 1 | 1 | 4 | 0 | 2.50 |
| Xeris Biopharma Competitors | 7859 | 13810 | 25855 | 1041 | 2.41 |
Xeris Biopharma presently has a consensus target price of $17.00, indicating a potential upside of 0.82%. As a group, “Pharmaceuticals” companies have a potential upside of 29.91%. Given Xeris Biopharma’s peers higher probable upside, analysts clearly believe Xeris Biopharma has less favorable growth aspects than its peers.
Institutional and Insider Ownership
42.7% of Xeris Biopharma shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 4.3% of Xeris Biopharma shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Xeris Biopharma and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xeris Biopharma | -1.76% | 147.75% | 6.03% |
| Xeris Biopharma Competitors | -2,391.72% | -204.89% | -14.89% |
Volatility & Risk
Xeris Biopharma has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Xeris Biopharma’s peers have a beta of -0.05, indicating that their average share price is 105% less volatile than the S&P 500.
Summary
Xeris Biopharma beats its peers on 7 of the 13 factors compared.
Xeris Biopharma Company Profile
Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative. The company also develops drug-delivery technologies intended to make medicines easier to store and administer.
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
